C4 Therapeutics (CCCC) Short-term Investments (2020 - 2026)

C4 Therapeutics' Short-term Investments history runs 7 years deep, the most recent figure standing at $174.4 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 6.47% year-over-year to $174.4 million in Q1 2026; TTM through Mar 2026 was $174.4 million, a 6.47% increase from a year earlier, with the FY2025 full-year figure at $173.9 million, down 8.17% from the prior year.
• Short-term Investments held at $174.4 million in Q1 2026 per CCCC's latest filing, from $173.9 million in the prior quarter.
• Across five years, Short-term Investments topped out at $264.1 million in Q3 2022 and bottomed at $127.1 million in Q4 2023.
• The 5-year median for Short-term Investments is $189.4 million (2024), against an average of $191.7 million.
• Across the five-year window, Short-term Investments tumbled 48.42% in 2023 and surged 49.03% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $246.4 million in 2022, then tumbled by 48.42% to $127.1 million in 2023, then soared by 49.03% to $189.4 million in 2024, then retreated by 8.17% to $173.9 million in 2025, then advanced by 0.27% to $174.4 million in 2026.
• Per Business Quant, the three latest CCCC Short-term Investments figures stand at $174.4 million (Q1 2026), $173.9 million (Q4 2025), and $133.1 million (Q3 2025).